Know Your Risk: How Subtypes Affect Heart and Lung Health

While all types of Limb-Girdle Muscular Dystrophy (LGMD) cause muscle weakness, they are not all the same “under the hood.” Different genetic subtypes carry very different risks for the heart and lungs ^[1]. Knowing your specific subtype name (the “D” or “R” number) is the only way for your care team to know which organs need the most attention and how often they should be checked ^[2].

High-Risk Subtypes: Heart and Lung Focus

Certain forms of LGMD are “systemic,” meaning the genetic mutation affects the heart muscle and the breathing muscles just as much as the legs and arms.

LGMDR9 (FKRP-related, formerly LGMD2I)

LGMDR9 is known for its significant impact on the heart and respiratory system.

• Cardiac Risk: This subtype carries a high risk for dilated cardiomyopathy—a condition where the heart becomes enlarged and weakened ^[3][4]. This risk increases as patients get older ^[3].
• Respiratory Risk: Weakness in the diaphragm often leads to sleep-disordered breathing ^[5]. Patients may eventually require nocturnal ventilation (a machine to help them breathe at night) ^[6].
• Monitoring: Annual heart and lung check-ups are typically standard for this group ^[3][5].

Sarcoglycanopathies (LGMDR3, R4, R5, R6)

These four subtypes are caused by mutations in the sarcoglycan proteins.

• Systemic Risk: Like LGMDR9, these types frequently involve both the heart and the lungs ^[7].
• Progression: These are often more progressive, and monitoring for heart failure and respiratory insufficiency must start early in the diagnostic journey ^[7][8].

Subclinical and Late-Onset Risks

Some subtypes primarily affect the skeletal muscles but still require a “watchful eye” on other systems.

LGMDR2 (Dysferlinopathy, formerly LGMD2B)

In LGMDR2, the heart is usually not the primary concern, but it is not entirely unaffected.

• “Subclinical” Involvement: More than one-third of patients with LGMDR2 show “subclinical” changes—meaning the heart may show signs of weakness on an echocardiogram even if the patient feels perfectly fine ^[9].
• Baseline Checks: Because of this, a baseline heart evaluation is recommended for everyone with this subtype ^[9].

LGMDR1 (Calpainopathy, formerly LGMD2A)

LGMDR1 is often considered a “pure” skeletal muscle disorder, but there is one important exception.

• Respiratory Alert: While heart issues are rare in LGMDR1, patients can still develop respiratory insufficiency later in the disease ^[10][11].
• Symptoms: If you experience shortness of breath or morning headaches, it may be a sign that the breathing muscles are weakening, even if your mobility remains stable ^[10].

Summary of Monitoring Needs

Terms: Echocardiogram (Echo) is an ultrasound of the heart; Pulmonary Function Test (PFT) measures how well your lungs are working.

Identifying your subtype early allows you to transition from “reactive” care (treating symptoms after they appear) to “proactive” care (screening to prevent complications before they start) ^[2].